Liraglutide

Overview

Liraglutide (development code NN2211; brand names Victoza and Saxenda) is a glucagon-like peptide-1 (GLP-1) receptor agonist given by once-daily subcutaneous injection. Unlike many peptides documented on this site, liraglutide is a fully approved prescription medicine in both the United States and the European Union. The same active molecule is sold under two brand names at two different dose ranges:

• Victoza — for type 2 diabetes (glycemic control), at doses up to 1.8 mg/day. In the United States it also carries an indication to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
• Saxenda — for chronic weight management, at a higher dose of 3.0 mg/day, alongside a reduced-calorie diet and increased physical activity.

Liraglutide was one of the first GLP-1 receptor agonists to reach the market (EU approval in 2009, US in 2010) and the first drug of its class to demonstrate a cardiovascular benefit in a dedicated outcomes trial. It is, however, an older agent: its average weight-loss effect is meaningfully smaller than that of the newer, longer-acting once-weekly drugs Semaglutide and Tirzepatide. For context on the broader drug class, see the Weight management hub.

Chemistry and structure

Liraglutide is an acylated analog of human GLP-1. It is based on the native human GLP-1(7-37) sequence and shares roughly 97% of its amino-acid identity, with two engineered modifications that extend its duration of action:

1. An arginine-for-lysine substitution at position 34 (Arg34).
2. A C16 fatty-acid chain (palmitic acid) attached through a glutamic-acid (gamma-Glu) spacer to the lysine at position 26 (Lys26).

The fatty-acid chain allows liraglutide to bind reversibly to albumin in the bloodstream. This albumin binding, together with self-association and resistance to the enzyme dipeptidyl peptidase-4 (DPP-4), slows clearance dramatically. Native GLP-1 has a half-life of only about 1.5 to 2 minutes; liraglutide's is approximately 13 hours, which is what makes once-daily dosing possible.

Mechanism of action

Liraglutide activates the GLP-1 receptor, mimicking the action of the natural incretin hormone GLP-1, which the gut releases in response to food. Its effects include:

• Glucose-dependent insulin secretion: it stimulates insulin release from pancreatic beta cells only when blood glucose is elevated, which lowers the risk of hypoglycemia when used on its own.
• Suppression of glucagon: it reduces inappropriately high glucagon secretion, decreasing hepatic glucose output.
• Slowed gastric emptying: food leaves the stomach more slowly, blunting post-meal glucose spikes and increasing satiety.
• Central appetite regulation: by acting on GLP-1 receptors in the brain (including the hypothalamus), it reduces appetite and food intake. This is the basis for its weight-management effect.

The same mechanism underlies its use in both diabetes and obesity; the higher 3.0 mg dose used for weight management produces a greater appetite and body-weight effect than the lower diabetes doses.

Clinical evidence

Liraglutide is supported by a large randomized-trial program (the LEAD trials in diabetes, the SCALE trials in weight management, and the LEADER cardiovascular-outcomes trial). Selected pivotal results follow.

LEADER (Marso et al., NEJM 2016), cardiovascular outcomes. This double-blind trial randomized 9,340 adults with type 2 diabetes at high cardiovascular risk to liraglutide or placebo on top of standard care, with a median follow-up of 3.8 years. The primary composite outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 13.0% on liraglutide versus 14.9% on placebo (hazard ratio 0.87; 95% CI 0.78 to 0.97). Cardiovascular death and all-cause mortality were also reduced. LEADER established liraglutide as the first GLP-1 receptor agonist to show a cardiovascular benefit in a dedicated outcomes trial, and it supports the Victoza cardiovascular indication.

SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015), weight management. This 56-week, double-blind trial enrolled 3,731 adults without type 2 diabetes who had a BMI of at least 30 (or at least 27 with weight-related comorbidity). At week 56, the liraglutide 3.0 mg group lost on average 8.4 kg versus 2.8 kg on placebo (a placebo-adjusted difference of about 5.6 kg, roughly 5 to 6 percentage points of body weight). More liraglutide-treated participants achieved 5% and >10% weight loss. These results supported the Saxenda approval.

STEP 8 (Rubino et al., JAMA 2022): head-to-head versus semaglutide. This is the key direct comparison for weight loss. In adults with overweight or obesity without diabetes, once-weekly semaglutide 2.4 mg produced about 15.8% mean weight loss versus about 6.4% for once-daily liraglutide 3.0 mg at 68 weeks, a difference of roughly 9 percentage points favoring semaglutide. This trial is the clearest evidence that liraglutide, while effective, delivers less average weight loss than the newer once-weekly GLP-1 drug.

Safety and risks

Liraglutide's safety profile reflects both the known effects of GLP-1 receptor agonism and class-specific warnings. The points below summarize the U.S. prescribing information for Victoza and Saxenda.

Contraindications (per label):

• Personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Known serious hypersensitivity to liraglutide.
• Saxenda is contraindicated in pregnancy (weight loss offers no benefit during pregnancy and may cause fetal harm).

Warnings and precautions:

• Acute pancreatitis: pancreatitis has been reported; liraglutide should be discontinued if pancreatitis is suspected. The causal relationship remains a recognized but unconfirmed signal.
• Gallbladder disease (cholelithiasis/cholecystitis): gallstones and gallbladder inflammation occur more often, particularly with the higher weight-management dose and with rapid weight loss.
• Hypoglycemia: the risk rises when liraglutide is combined with insulin or insulin secretagogues (such as sulfonylureas); dose reduction of those agents may be needed.
• Acute kidney injury: dehydration from nausea, vomiting, or diarrhea can precipitate renal impairment.
• Heart-rate increase: liraglutide can modestly raise resting heart rate.
• Suicidal behavior and ideation: monitoring for depression or suicidal thoughts is advised with weight-management use (Saxenda).
• Hypersensitivity reactions: including, rarely, anaphylaxis and angioedema.

Common adverse reactions: the most frequent side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation, dyspepsia, and abdominal pain) and are usually most pronounced during dose escalation. Injection-site reactions and headache are also reported. These GI effects are a leading reason people discontinue therapy.

Regulatory status (FDA / EMA)

United States (FDA-approved):

• Victoza was approved in 2010 for glycemic control in type 2 diabetes (doses up to 1.8 mg/day). It later gained an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, based on LEADER.
• Saxenda was approved on December 23, 2014, for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity, and later for adolescents aged 12 and older meeting specified criteria.
• A generic liraglutide injection has since been approved in the United States.

European Union (EMA-approved):

• Victoza received an EU-wide marketing authorization on 30 June 2009 for type 2 diabetes (doses up to 1.8 mg/day).
• Saxenda received an EU-wide marketing authorization on 23 March 2015 for weight management, at up to 3.0 mg/day, in adults meeting BMI criteria and (in later updates) in eligible adolescents.

Liraglutide is therefore a prescription medicine approved in both the US and the EU for diabetes and for weight management. It is not an unregulated "research chemical."

How it compares

Liraglutide is an effective, well-established GLP-1 drug, but it is older and shorter-acting than the agents that followed it:

• Semaglutide is a once-weekly GLP-1 receptor agonist (Ozempic for diabetes, Wegovy for weight management) with a longer half-life (~1 week) and, in head-to-head testing (STEP 8), substantially greater average weight loss than liraglutide.
• Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound) that has produced the largest average weight loss among approved incretin drugs to date, generally exceeding both liraglutide and semaglutide.

The practical trade-offs are clear: liraglutide requires a daily injection rather than a weekly one and tends to deliver less weight loss on average, but it has a long track record, a positive cardiovascular-outcomes trial (LEADER), and, increasingly, generic availability. The choice among these drugs is an individualized clinical decision. For the broader picture of how these agents are used, see the Weight management hub.

Common misconceptions

---

This article is provided for educational purposes only and is not medical advice. Liraglutide (Victoza, Saxenda) is a prescription medication that should be used only under the supervision of a qualified healthcare professional, who can assess contraindications, weigh risks and benefits, and provide appropriate monitoring. Nothing here should be interpreted as encouragement to obtain or use liraglutide outside an approved, supervised clinical context.